Scale and capital Forbion manages just over €5 billion across multiple fund strategies and operates globally with a focus on European biotech, presenting a strong capacity for multi‑year, large‑ticket investments and potential co‑investment opportunities with portfolio companies seeking expansion or rounds.

BioEconomy focus The firm’s dedicated BioEconomy Fund I targets biology based industrial sustainability solutions across food, agriculture, materials and environmental tech, signaling a strategic opportunity to partner with portfolio companies or funds addressing planetary health needs and sustainability driven growth.

Planetary health leadership Leadership additions and structural focus on planetary health, including appointing Joy Faucher as General Partner, indicate a proactive stance to scale the BioEconomy strategy and attract co‑investors, advisers, and portfolio companies aligned with sustainable tech and circular economy themes.

Active deal cadence Recent notable investments across seed to Series A in biotechnology and biomaterials (Seamless Therapeutics, LoQus23 Therapeutics, Pact, EEDEN) demonstrate a robust deal flow and the ability to co‑invest with other major players, providing multiple entry points for follow‑on financing and strategic partnerships.

Corporates and LPs With backing from and collaboration potential with large investors (Wellington Management, Dementia Discovery Fund, Novartis Venture Fund, HV Capital) and a corporate‑adjacent acquisition vehicle, there are opportunities to introduce corporate collaborations, co‑development deals, and LP‑led co‑investments leveraging established networks.